AstraZeneca PLC 🇬🇧
AZN • Healthcare • United Kingdom
💡 Institutional Quantitative Investment Thesis
High-quality compounder passing 8/9 fundamental checks. Strong balance sheet with Forward PER compression (17.1x vs 25.6x) and robust Free Cash Flow generation.
📊 Frequently Asked Questions & Related Moat Stocks
1. What is AstraZeneca PLC (AZN)'s Economic Moat Score in 2026?
In 2026, AstraZeneca PLC (AZN) holds a proprietary MoatPicks Economic Moat Score™ of 77.0/100 (Wide Economic Moat). This 12-point fundamental audit evaluates AZN's 81.7% gross margin, $5.1B free cash flow generation, +6.4% YoY revenue growth, and 1.6x Debt/EBITDA ratio. You can benchmark any stock's competitive durability interactively with our Economic Moat Score™ Checker.
2. Is AZN stock undervalued right now based on P/E and PEG ratio?
Yes — AZN currently screens as undervalued on a growth-adjusted basis with a Peter Lynch PEG ratio of 0.95x (below the 1.2x GARP threshold) and a Forward P/E of 17.1x. At a share price of $171.49, investors can stress-test AZN's fair value using the MoatPicks Economic Moat Score™ Checker and FIRE compounding calculators. Model how compounding AZN fits your long-term retirement target in our FIRE Financial Independence Calculator.
3. Which superinvestors and 13F hedge funds own AZN stock?
AstraZeneca PLC (AZN) is actively monitored across our 25 tracked 13F superinvestor portfolios and institutional quality screens. Institutional capital focuses on AZN's 81.7% gross margin, $5.1B free cash flow, and 1.6x Debt/EBITDA balance sheet.